Articles
An integrated palliative and respiratory care service for
patients with advanced disease and refractory breathlessness:
a randomised controlled trial
Irene J Higginson, Claudia Bausewein, Charles C Reilly, Wei Gao, Marjolein Gysels, Mendwas Dzingina, Paul McCrone, Sara Booth,
Caroline J Jolley, John Moxham
Summary
Background Breathlessness is a common and distressing symptom, which increases in many diseases as they progress Lancet Respir Med 2014;
and is diffi cult to manage. We assessed the eff ectiveness of early palliative care integrated with respiratory services for 2: 979–87
patients with advanced disease and refractory breathlessness. Published Online
October 29, 2014
http://dx.doi.org/10.1016/
Methods In this single-blind randomised trial, we enrolled consecutive adults with refractory breathlessness and
S2213-2600(14)70226-7
advanced disease from three large teaching hospitals and via general practitioners in South London. We randomly
See Comment page 944
allocated (1:1) patients to receive either a breathlessness support service or usual care. Randomisation was computer
See Online for for podcast
generated centrally by the independent Clinical Trials Unit in a 1:1 ratio, by minimisation to balance four potential
interview with Irene Higginson
confounders: cancer versus non-cancer, breathlessness severity, presence of an informal caregiver, and ethnicity. The
Cicely Saunders Institute,
breathlessness support service was a short-term, single point of access service integrating palliative care, respiratory Department of Palliative Care,
medicine, physiotherapy, and occupational therapy. Research interviewers were masked as to which patients were in Policy and Rehabilitation
the treatment group. Our primary outcome was patient-reported breathlessness mastery, a quality of life domain in (Prof I J Higginson PhD,
Prof C Bausewein PhD,
the Chronic Respiratory Disease Questionnaire, at 6 weeks. All analyses were by intention to treat. Survival was a
C C Reilly PhD, W Gao PhD,
safety endpoint. This trial is registered with ClinicalTrials.gov, number NCT01165034. M Gysels PhD, M Dzingina MSc),
Institute of Psychiatry
Findings Between Oct 22, 2010 and Sept 28, 2012, 105 consenting patients were randomly assigned (53 to breathlessness (Prof P McCrone PhD), and
Department of Respiratory
support service and 52 to usual care). 83 of 105 (78%) patients completed the assessment at week 6. Mastery in the
Medicine (C J Jolley PhD,
breathlessness support service group improved compared with the control (mean diff erence 0∙58, 95% CI 0∙01–1∙15, Prof J Moxham MD), King’s
p=0∙048; eff ect size 0∙44). Sensitivity analysis found similar results. Survival rate from randomisation to 6 months College London, Denmark Hill,
was better in the breathlessness support service group than in the control group (50 of 53 [94%] vs 39 of 52 [75%]) and London, UK; Palliative Care
Department, Cambridge
in overall survival (generalised Wilcoxon 3·90, p=0∙048). Survival diff erences were signifi cant for patients with
University Hospitals NHS
chronic obstructive pulmonary disease and interstitial lung disease but not cancer. Foundation Trust, Cambridge,
UK (S Booth MD); University of
Interpretation The breathlessness support service improved breathlessness mastery. Our fi ndings provide robust Amsterdam, Centre for Social
Science and Global Health,
evidence to support the early integration of palliative care for patients with diseases other than cancer and
Amsterdam, Netherlands
breathlessness as well as those with cancer. The improvement in survival requires further investigation. (M Gysels); and Department of
Palliative Medicine, Munich
University Hospital, Munich,
Funding UK National Institute for Health Research (NIHR) and Cicely Saunders International.
Germany (Prof C Bausewein)
Correspondence to:
Copyright ©Higginson et al. Open Access article distributed under the terms of CC BY.
Prof Irene J Higginson, Cicely
Saunders Institute, Department
Introduction disease have many symptoms and concerns that are of Palliative Care, Policy and
Breathlessness is a common and distressing symptom in complex and interact; consequently palliative care has Rehabilitation, King’s College
London, Denmark Hill, London
many advanced chronic diseases, causing considerable been recommended.4,9 In this study, we developed and
SE5 9PJ, UK
disability, anxiety, and social isolation.1–3 Worldwide, more assessed a new short-term breathlessness support service. irene.higginson@kcl.ac.uk
than 75 million people have breathlessness every year, This provided one point of access for patients, brought
including more than 90% of the 65 million people with together palliative care and respiratory medicine, and
severe lung disease,4 more than 50% of the 10 million with responded to the call for shared care at an earlier stage in
incurable cancer, and 50% of the 23 million with heart disease than usual.10,11 We hypothesised that patients
failure.5,6 Breathlessness increases as the disease attending the breathlessness support service, compared
progresses,7 is frightening for patients and families, and with those receiving standard care, would have better
often results in emergency hospital admission because it mastery of breathlessness at 6 weeks.
is accompanied by feelings of loss of mastery over
breathing and panic.7, 8 Methods
Once treatment of the underlying disease is optimised, Study design and participants
breathlessness that continues is deemed refractory.1 This trial was a randomised controlled, parallel group,
Patients with refractory breathlessness in advanced pragmatic, single-blind fast-track trial in South London,
www.thelancet.com/respiratory Vol 2 December 2014 979
Articles
UK, recruiting patients between Oct 22, 2010 and Randomisation and masking
Sept 28, 2012. We screened for potential patients across Using data from the baseline interview, the King’s Clinical
three large teaching hospitals and via general Trials Unit’s Online randomisation system, independent
practitioners. of research and clinical teams, randomly assigned (1:1)
Patients were included according to a standard patients to the intervention (immediate access to
proforma completed by the identifying clinician. breathlessness support service in addition to standard
Patients had to meet all criteria: refractory breathlessness care) or control group (standard best practice; off ered
on exertion or rest (MRC dyspnoea scale score ≥2), breathlessness support service after 6 weeks). Allocation
despite optimum treatment of the underlying disease, was done by minimisation13 to balance four potential
as deemed by the identifying clinician; advanced disease confounders: cancer versus non-cancer, breathlessness
such as cancer, chronic obstructive pulmonary disease severity (numerical rating scale >3 or not), presence (or
(COPD), chronic heart failure, interstitial lung disease, not) of an informal caregiver, and ethnic origin (white or
and motor neuron disease; willing to engage with short- other). After randomisation, the clinical trials unit team
term home physiotherapy and occupational therapy; informed the breathlessness support service clinic
and able to provide informed consent. Patients were administrator of the patient’s study group via secure email,
excluded for any of the following: breathlessness of who then arranged clinic appointments accordingly.
unknown cause; a primary diagnosis of chronic Research nurses and interviewers were masked to
hyperventilation syndrome; completely house (or treatment allocation. Patients were aware of treatment
hospital or nursing home) bound, despite off er of free allocation, and were asked not to disclose this information
transport to clinic; or within 2 weeks of treatment for an to interviewers or research nurses. The trial coordinator
acute exacerbation. Such patients were reapproached and the trial administrator were aware of treatment
after 2 weeks. allocation; the coordinator informed the research nurses
Protocol, procedures, information sheets, consent when, and with whom, they had to do interviews.
forms, and questionnaires were approved through the
indep endent UK Integrated Research Approval System Procedures
via the ethics committee at King’s College Hospital The breathlessness support service is an additional service
(Ref. 10/H0808/17). We then applied for and were to usual UK National Health Service (NHS) care. It is a
granted NHS Research and Development approval in multi-professional integrated service that combines
all recruiting sites. Patients gave written informed respiratory, physiotherapy, occupational therapy, and
For Protocol see http://www.
consent before enrolment. Our protocol12 followed palliative care assessment and management. It brings
biomedcentral.com/content/
pdf/1471-2466-12-58.pdf CONSORT recommendations. There were no protocol together assessment and treatment of physical, emotional,
See Online for appendix deviations. psychological, and spiritual concerns, through one point of
access. The service comprises (appendix pp 1–2) a fi rst
outpatient clinic appointment with respiratory medicine
Panel 1: Outcome, quality of life and health-care use assessments and palliative care clinicians assessing present treatment
and concerns. The patient (and family if present) is given a
• Chronic Respiratory Disease Questionnaire, a 20-item validated health-related quality
breathlessness pack including information, management,
of life questionnaire in which experiences are rated on seven-point scales ranging 1
and pacing guidance, a hand-held fan or water spray, and a
(maximum impairment) to 7 (no impairment)19,20
poem (a short mantra to help breathing and relaxation
• Severity of breathlessness in the previous 24 h on a 0–10 numerical rating scale
during crises) and helped to agree a crisis plan. A home
(NRS), average, at rest, and on exertion12
assessment is done 2–3 weeks after the clinic visit by a
• London Chest Activity of Daily Living, a questionnaire of the level of disability induced by
physiotherapist and/or occupational therapist to assess the
breathlessness for 15 activities (in four areas: personal care, domestic, physical, and
need for walking and home aids and adaptations,
social); each activity is scored 0–5 (0=I wouldn’t do it anyway, 5=someone else needs to
reinforcement of self-management, and further guidance
carry out the activity)12
on pacing and exercises, including a DVD when
• EQ-5D and EQ-VAS which assess mobility, self-care, usual activities, pain or
appropriate. 4 weeks after the fi rst clinic visit, a second and
discomfort, anxiety or depression according to three levels of severity (1=no problems,
fi nal clinic appointment with a palliative care specialist is
2=some or moderate problems, and 3=extreme problems), plus a Visual Analogue
arranged to agree further actions and a discharge plan.
Scale (VAS) of present health-related quality of life, scored 0–10012
Service modelling for the breathlessness support service
• Palliative care Outcome Scale, a ten-item measure for advanced disease widely
is built on the nurse-led clinic, developed by Bredin and
validated in cancer and non-cancer; each item is rated 0 (no problem) to
colleagues14 and the palliative care and physiotherapy
4 (overwhelming problem)21
approach developed by Booth and colleagues,15 and
• Hospital Anxiety and Depression Scale (HADS), a 14-item measure of psychological
systematic reviews,16 qualitative interviews,2 cross-
distress with separate anxiety and depression subscales12
sectional9,17 and longitudinal studies,18 and consultation
• Client Services Receipt Inventory (CSRI)12 in which patients reported the health,
with local stakeholders.12 These data suggested that
voluntary, and social care services received over the past 3 months, or if follow-up
breathlessness support services should provide one point
since the last research interview12
of access, integrate palliative care with existing services,
980 www.thelancet.com/respiratory Vol 2 December 2014
Articles
off er outpatient and home contact, and focus on improving
patient self-management. 216 referred to the trial and assessment for eligibility
Patients randomly assigned to the control group
continued with optimum management as provided by
11 did not meet inclusion criteria or met
their usual services in accordance with relevant UK exclusion criteria
guidance to ensure best practice (appendix pp 3–5). After 6 died at time of referral letter receipt
29 declined to participate
the 6 week (primary endpoint) research interview, these 18 too ill to participate
patients were off ered the breathlessness support service. 47 unable to contact*
Study measurements included the Chronic Respiratory
Disease Questionnaire, severity of breathlessness in the 105 underwent baseline interview
previous 24 h, the London Chest Activity of Daily Living
questionnaire, EQ-5D and EQ-VAS, the Palliative care
105 randomly assigned
Outcome Scale, the Hospital Anxiety and Depression
Scale (HADS), and the Client Services Receipt Inventory
(panel 1). These measurements were collected in a
standard questionnaire booklet consisting of demographic, 53 assigned to breathlessness 52 assigned to usual care
support service (control)
clinical, outcome assessments, and use of health-care
services. Research data were collected in face to face
interviews with patients, usually in their own homes, at 1 died 3 died
2 withdrew from study, 3 withdrew from study,
baseline and 6 weeks follow-up (the primary endpoint). In
no reason offered no reason offered
addition face to face qualitative interviews were conducted 4 withdrew due to illness 4 withdrew due to illness
after the trial was completed. 4 unable to contact, patient 2 unable to contact, patient
often hospitalised or moved often hospitalised or moved
At baseline and 6 weeks follow-up, interviewers away away
measured pulmonary function and oxygen saturation with
a portable spirometer and fi nger pulse oximeter.
42 interviewed (6 weeks) 40 interviewed (6 weeks)
Outcomes
The primary outcome was breathlessness mastery at 0 excluded from analysis 0 excluded from analysis
6 weeks as recorded in the 6 week face to face interview,
determined according to one domain of the quality of life 42 analysed 40 analysed
measure, the Chronic Respiratory Disease Questionnaire12,19
(panel 1). Mastery is the average of four questions about Figure 1: Trial profi le
the feeling of control over the disease and its eff ects on *Our biggest loss before consent was the 47 individuals (21·8% of 216 referred to the trial, and 42·3% of those not
consented and randomly assigned) whom we were unable to contact. Appendix p 9 shows the eff orts made to
quality of life and function (range=1 [maximum
contact people.
impairment] to 7 [no impairment]). Secondary outcomes
included: severity of breathlessness on exertion in the
previous 24 h, activity (assessed by London Chest Activity interviews were semi-structured and followed a topic
of Daily Living questionnaire), other domains of the guide on patients’ expectations, experiences, and views
Chronic Respiratory Disease Questionnaire (breathless- about the content, format, and eff ect of the breathlessness
ness, fatigue, and emotional function), quality of life (EQ- support service. Questions were open-ended and not
5D), palliative needs (assessed by Palliative care Outcome based on pre-existing theory. Interviews were tape-
Scale), depression and anxiety (measured by the Hospital recorded and transcribed verbatim.
Anxiety and Depression Scale [HADS]), and spirometry.
Patient survival (since randomisation) was planned to be Statistical analysis
calculated from dropout and missing data, with exact dates On the basis of our primary outcome, the Chronic
extracted from clinical records, as a safety secondary Respiratory Disease Questionnaire mastery domain, we
endpoint, as recommended in clinical trials.22 We also estimated that more than 34 patients per group would
planned to collect and analyse caregiver burden data. But it detect a mean diff erence of 0∙70 (SD 1), a p value of less
proved diffi cult to contact lay caregivers for consent than 0∙05 at power 80%.19,20 To allow for a conservative
because many used the research nurse visit as an estimated attrition of 40% we planned to recruit at least
opportunity to go out while someone was with the patient. 110 patients into the study.
Only 11 caregivers were interviewed at baseline and only All randomly assigned participants were included in
four at 6 week follow-up. Therefore these data were not the intention-to-treat analysis. Missing data were explored
analysed further. according to cause.23 Continuous variables, expressed as
20 patients were purposefully selected for qualitative means and standard deviations, were compared with the
interviews, after completing the trial, to include a mix of Student’s t test. Categorical variables were compared with
ages, sex, diagnoses, and presence of caregiver. The χ² test or Fisher’s exact test, as appropriate. As
www.thelancet.com/respiratory Vol 2 December 2014 981
Articles
prespecifi ed, we used independent samples Student’s t
Overall (n=105) Breathlessness Control group
test to compare patient mastery (primary outcome) and
support service (n=52)
group (n=53) secondary outcomes at 6 weeks, by trial group. Sensitivity
analysis explored the robustness of results: fi rst,
Age (years) 67 (10) 66 (11) 68 (11)
accounting for diff erences in patient diagnoses and
Sex
baseline scores using analysis of covariance (ANCOVA);
Men 61 (58%) 28 (53%) 33 (63%)
second, with multiple imputations of missing data;23 and
Women 44 (42%) 25 (47%) 19 (37%)
third with pre-post analysis of breathlessness support
Diagnosis
service and control groups.
Chronic obstructive pulmonary disease 57 (54%) 29 (55%) 28 (54%)
Survival was calculated from date of randomisation to
Cancer* 21 (20%) 11 (21%) 10 (19%)
date of death and plotted using the Kaplan-Meier method.
Interstitial lung disease 19 (18%) 7 (13%) 12 (23%)
Patients who were still alive on Sept 1, 2013, after the last
Heart failure 5 (5%) 4 (8%) 1 (2%)
patient was recruited were censored at this date. We
Other† 3 (3%) 2 (4%) 1 (2%)
calculated the survival rates to 180 days (6 months) from
Has carer or family member
consent in both groups. With all data to 1 year from last
Yes 75 (71%) 38 (72%) 37 (71%)
recruitment, we assessed overall survival diff erence
No 30 (29%) 15 (28%) 15 (29%) between two groups with the generalised Wilcoxon
Clinical characteristics (Breslow) test, which is more sensitive in the detection of
FEV 1 (L)‡ 1·25 (0·70) 1·3 (0·78) 1·2 (0·65) early diff erences in survival,24 which is important in the
Predicted FEV 1 (%)‡ 46·2 (23·3) 48·0 (24·3) 44·5 (22·4) fast-track or wait-list design.
VC (L)‡ 1·9 (0·96) 2·0 (1·0) 1·8 (0·9) We calculated costs by combining Client Service
Predicted VC (%)‡ 57·9 (25·7) 59·3 (25·5) 56·6 (26·0) Receipt Inventory data with UK 2011–12 unit costs.25 Cost
FEV 1/VC (%) 65·0 (19·0) 64·5 (19·4) 65·5 (18·8) data are usually skewed; therefore, we used a bootstrapped
PEF (L/min) 227·3 (124·5) 232·5 (118) 222·3 (130) regression model to produce confi dence intervals.
SaO%‡§ 93·6 (3·9) 93·8 (4·0) 93·3 (3·7) Statistical signifi cance was accepted for p values less
2
Quality of life measures than 0∙05.
NRS breathlessness average 24 h (0–10)¶ 5·9 (2·0) 6·2 (2·0) 5·7 (1·9) Qualitative interviews were imported into NVivo version
NRS breathlessness worst at rest (0–10)¶ 4·9 (2·6) 5·1 (2·7) 4·8 (2·6) 7 and content analysis explored patients’ own views and
NRS breathlessness on exertion 24 hours 8·3 (1·4) 8·4 (1·5) 8·3 (1·4) experiences of the breathlessness support service, and in
(0–10)¶ particular how issues related to the primary and secondary
CRQ HRQL (score range 20–140)‡ 60·9 (19·1) 59·3 (18·7) 62·7 (19·6) outcomes. We created categories inductively, with attention
CRQ dyspnoea (score range 1–7)‡|| 2·2 (0·80) 2·1 (0·7) 2·3 (0·9) to terms and content, from the interview data. Through a
CRQ emotion (score range 1–7)‡|| 3·6 (1·3) 3·6 (1·3) 3·7 (1·3) process of constant integration of categories and their
CRQ fatigue (score range 1–7)‡|| 2·9 (1·3) 2·7 (1·2) 3·0 (1·3) properties, or constant comparison, the fi ndings became
CRQ mastery (score range 1–7)‡|| 3·4 (1·5) 3·5 (1·4) 3·3 (1·5) relevant at a more abstract level. We used simple counting
EQ-5D index‡** 0·35 (0·33) 0·37 (0·32) 0·34 (0·34) when possible to discover more defi nite patterns in views.
EQ-5D-HRQL VAS (score range 0–100)‡ 51 (20) 52 (18) 50 (22) Member checks and teamwork were used to establish
LCADL total score (score range 0–75)¶ 44·6 (12·9) 45·1 (13·9) 44·2 (12·2) credibility.
POS total score (score range 0–40)¶ 15·1 (6·5) 15·4 (6·0) 14·8 (6·9) This trial is registered with ClinicalTrials.gov, number
HADS anxiety (score range 0–21)¶ 9·2 (2·7) 9·5 (3·0) 9·0 (2·3) NCT01165034.
HADS depression (score range 0–21)¶ 9·9 (3·2) 10·0 (3·0) 9·9 (3·3)
Costs and health-care use Role of the funding source
Hospital inpatient days in previous 3 months 4·5 (7·2) 4·5 (6·8) 4·6 (7·6) The funders of the study had no role in study design,
Cost of formal care in the previous 3 months £3390 (3749) £2911 (2729) £3709 (4484) data collection, data analysis, data interpretation, or
writing of the report. The corresponding author had full
Data are absolute numbers or mean (SD) unless otherwise stated. FEV=forced expiratory volume in 1 s. PEF=peak
1 access to all the data in the study and had fi nal
expiratory fl ow. VC=vital capacity. POS=Palliative care Outcome Scale. POS-S=Palliative care Outcome Scale-Symptom
Score. CRQ=Chronic Respiratory Questionnaire. HRQL= health-related quality of life. HRQL VAS= health-related quality of responsibility for the decision to submit for publication.
life visual analogue scale. LCADL=London Chest Activity of Daily Living scale. HADS=Hospital Anxiety and Depression
Scale. SaO%=oxygen saturation. NRS=numerical rating scale. *Appendix p 6 shows breakdown of primary cancer type. Results
2
†Other diagnoses were: left lower lobe collapse of unknown aetiology associated with severe symptoms; lupus, shrinking
Between Oct 22, 2010, and Sept 28, 2012, we screened
lung syndrome, and rheumatoid arthritis; severe asthma and gastro-oesophageal refl ux disease. ‡Scale interpretation:
high score better. §Measured for 13 patients (three in breathlessness support service group and ten in control group) 216 eligible patients. 105 consented and were randomly
while on supplemental oxygen (mean [SD] SaO 2 91·8 [5·1]) and the remainder on room air (mean [SD] 93·8 [3·6]). ¶Scale assigned (fi gure 1). Participants were identifi ed from
interpretation: high score worse. ||CRQ subdomains averaged on the 1–7 scale to give comparability across subscales.
respiratory medicine (50 [48%]), palliative care services
**EQ-5D index scores based on the standard UK population-based preference weights with the standard scoring
algorithm; 0·0=death and 1·0=perfect health. (23 [22%]), general practices (15 [14%]), physiotherapy
services (13 [12%]), and heart failure services (four [4%]).
Table 1: Baseline characteristics
The median time to fi rst clinic appointment was 19 days,
some patients were delayed beyond this because of health
982 www.thelancet.com/respiratory Vol 2 December 2014
Articles
problems or hospital admissions. Table 1 shows the
Breathlessness Control group Diff erence between p value
baseline characteristics. Patients had severe disease:
support service (n=40) breathlessness support
forced expiratory volume in 1 s (FEV) was 46% predicted, group (n=42) service and control (95% CI)
1
vital capacity 58% predicted, oxygen saturation (SaO%) at
2 Primary outcome (CRQ 4·15 (1·7) 3·57 (1·4) 0·58 (0·01 to 1·15) 0·048
rest 93%, average breathlessness 5∙9/10, on exertion mastery)*†
8∙3/10. Their average Chronic Respiratory Questionnaire Secondary outcomes
breathlessness mastery was 3∙4. Their average total NRS breathlessness 5·38 (2·2) 5·71 (2·1) –0·33 (–1·28 to 0·62) 0·49
Palliative care Outcome Score was 15/40, indicating average 24 h‡
important unmet palliative care concerns; for the HADS, NRS breathlessness 4·12 (2·8) 4·47 (3·3) –0·35 (–1·71 to 1·01) 0·61
the mean scores were 9 for anxiety and 10 for depression, worst at rest 24 h‡
both above the cutoff for clinical signifi cance. NRS breathlessness on 7·45 (2·4) 8·18 (1·8) –0·73 (–1·69 to 0·22) 0·13
exertion 24 h‡
At week 6, 82 of 105 (78%) patients completed
CRQ HRQL* 71 (19) 67 (20) 4·21 (–4·52 to 12·94) 0·34
assessments. The main reasons for attrition were illness
CRQ dyspnoea*† 2·54 (1·1) 2·46 (0·9) 0·08 (–0·38 to 0·52) 0·75
or death (fi gure 1). Attrition to the primary outcome was
CRQ emotion*† 4·07 (1·3) 3·93 (1·3) 0·14 (–0·42 to 0·71) 0·16
slightly lower than estimated (22% not 40%); therefore,
CRQ fatigue*† 3·09 (1·1) 3·07 (1·5) 0·02 (–0·56 to 0·62) 0·93
we agreed to stop recruitment after 105 patients had
consented. Missing data, death, and dropout were not EQ-5D index* 0·44 (0·31) 0·35 (0·29) 0·092 (–0·23 to 0·04) 0·18
associated with baseline mastery score, FEV or other EQ-5D HRQL VAS* 56 (20) 55 (18) 1 (–6·67 to 10·34) 0·67
1
key variables except oxygen saturation (appendix p 7). LCADL total score‡ 45 (13) 50 (15) –5 (–12·22 to 1·02) 0·10
Four patients died by week 6, two had cancer (one in POS total score‡ 12·15 (6·8) 12·42 (6·5) –0·27 (–3·29 to 2·75) 0·86
breathlessness support service group), and two had HADS anxiety‡ 9·2 (2·8) 9·1 (2·7) 0·1 (–0·93 to 1·24) 0·78
interstitial lung disease (both in control group). HADS depression‡ 10 (2·8) 11 (2·5) –1 (–1·82 to 0·30) 0·16
We recorded a signifi cant improvement in the primary Days in hospital, since 0·8 (3·6) 1·3 (4·3) –0·52 (–0·14 to 1·91) 0·58
randomisation
outcome, the mastery domain of the Chronic Respiratory
Spirometry
Disease Questionnaire, in the breathlessness support
FEV(L)* 1·30 (0·78) 1·29 (0·62) 0·11 (–0·26 to 0·48) 0·56
service group compared with the control group at 6 weeks 1
(table 2). Patients receiving the breathlessness support Vital capacity (L)* 2·01 (1·10) 1·80 (0·96) 0·21 (–0·34 to 0·75) 0·44
service had on average a 16% improvement for PEF (L/min) 254·5 (141·9) 244·3(108·0) 10·3 (–59·9 to 80·5) 0·38
breathlessness mastery over the control group (mean SaO 2%* 93·0 (4·4) 94·2 (3·1) –1·19 (–3·01 to 0·64) 0·17
diff erence 0·58, eff ect size 0·44, control group mean
Data are mean (SD) unless otherwise stated. p values were calculated with two-sided Student’s t test for independent
score 3·57). Results were similar to those from our samples. CRQ=Chronic Respiratory Disease Questionnaire. NRS=numerical rating scale. HRQL=Health-related Quality of
sensitivity analysis of the primary outcome: ANCOVA Life. EQ-5D=quality of life. LCADL=London Chest Activity of Daily Living survey. POS=Palliative care Outcome Scale.
HADS= Hospital Anxiety and Depression Scale. FEV=forced expiratory volume in 1 s. PEF=peak expiratory fl ow.
adjusted for diagnosis, p=0∙037; ANCOVA adjusted for 1
SaO%=oxygen saturation. *Scale interpretation; high score better. †CRQ sub-domains averaged on the 1–7 scale to give
diagnosis and baseline score, p=0∙05; multiple com2 parability across subscales. ‡Scale interpretation: high score worse.
imputation (number of imputations 45) based on
Table 2: Comparison of patient mastery (primary outcome) and secondary outcomes measured at
baseline score of the measure of interest, p=0∙07;
week 6 of study, by trial group
adjusted for baseline score, diagnosis, FEV, SaO %,
1 2
p=0∙072; control and intervention groups were imputed
separately. In further post-hoc sensitivity analyses, fi rst assessed by Chronic Respiratory Disease Questionnaire,
excluding patients referred or identifi ed via palliative average breathlessness per 24 h, on exertion breathlessness
care services, and second excluding those with cancer per 24 h, and Palliative care Outcome Scale total score. No
(because of potential bias of palliative care eff ect), we outcome showed deterioration. The control group had a
noted 6 week mean mastery scores of, respectively, 4·18 signifi cant improvement between baseline and 6 weeks
(SD 1·2) in the intervention group and 3·54 (1·4) in the for only Palliative care Outcome Scale total score, and
control group (p=0·043) and 4·19 (1·2) in the intervention signifi cant deteriorations for London Chest Activity of
group and 3·52 (1·3) in the control group (p=0·033). Daily Living questionnaire and HADS.
We noted no signifi cant diff erences in patient-reported We noted a signifi cant diff erence in survival for the
secondary outcomes between study groups at 6 weeks whole sample that appeared early after randomisation
(table 2). For all items, except anxiety, the breathlessness (generalised Wilcoxon 3·90, p=0∙048). Survival was
support service group had better scores than the control similar between the study arms for patients with cancer,
group; this was largest, but not signifi cant, for the London but signifi cantly diff erent for patients without cancer:
Chest Activity of Daily Living questionnaire and all 42 patients without cancer in the breathlessness
breathlessness on exertion. Findings of pre-post analysis support service group were alive through to 6 months
within groups (appendix p 8) showed signifi cant improve- (180 days), of the 42 control patients without cancer at
ments in the breathlessness support service group baseline, 38 were alive at 90 days, and 32 at 180 days
between baseline and 6 weeks for seven outcomes: (table 3 and fi gure 2). The standard care group received
mastery, total quality of life score, dyspnoea, and emotion, the breathlessness support service by 120 days.
www.thelancet.com/respiratory Vol 2 December 2014 983
Articles
Improved knowledge, confi dence, and insight into how
Enrolment Alive at Alive at Alive at Alive at
to function despite breathlessness were identifi ed as
(n) 45 days 90 days 120 days 180 days
(n, %) (n, %) (n, %) (n, %) potential mechanisms in the qualitative analysis through
which the breathlessness support service improved
Breathlessness support service
patient mastery (appendix pp 10–11).
Cancer 11 10 (91%) 9 (82%) 9 (82%) 8 (73%)
COPD 29 29 (100%) 29 (100%) 29 (100%) 29 (100%)
Discussion
Interstitial lung disease 7 7 (100%) 7 (100%) 7 (100%) 7 (100%)
This is the fi rst randomised trial of a breathlessness
Heart failure 4 4 (100%) 4 (100%) 4 (100%) 4 (100%)
support service integrating palliative care and respiratory
Other 2 2 (100%) 2 (100%) 2 (100%) 2 (100%)
medicine, and the fi rst powered trial to test early integrated
Total 53 52 (98%) 51 (96%) 51 (96%) 50 (94%)
palliative care including patients without cancer (panel 2).
All non-cancer 42 42 (100%) 42 (100%) 42 (100%) 42 (100%)
The breathlessness support service integrated respiratory
Control
medicine, palliative care, physiotherapy, and occupational
Cancer 10 9 (90%) 8 (80%) 7 (70%) 7 (70%)
therapy for patients with advanced conditions and
COPD 28 28 (100%) 26 (93%) 26 (93%) 22 (79%)
refractory breathlessness. The service responds to calls for
Interstitial lung disease 12 10 (83%) 10 (83%) 8 (67%) 8 (67%)
earlier integration of palliative care including for patients
Heart failure 1 1 (100%) 1 (100%) 1 (100%) 1 (100%) without cancer.10 At 6 weeks, the primary outcome,
Other 1 1 (100%) 1 (100%) 1 (100%) 1 (100%) breathlessness mastery, improved more in the
Total 52 49 (94%) 46 (88%) 43 (83%) 39 (75%) breathlessness support service group than in the standard
All non-cancer 42 40 (95%) 38 (90%) 36 (86%) 32 (76%) care group. Qualitative data provided evidence of the
breathlessness support service improving confi dence,
COPD=chronic obstructive pulmonary disease.
function, and control over breathlessness. No secondary
Table 3: Survival: number of patients alive by study group and diagnosis during the fi rst 6 months of patient-reported outcomes were signifi cantly diff erent
the study
between groups, although there was evidence in the pre-
post analysis that the breathlessness support service group
100 had improved activities of daily living and reduced
breathlessness on exertion and depression. We recorded
no harms of the breathlessness support service. The
80
number of inpatient bed days and total formal care costs,
on the basis of patient-reported total service use, were
60 similar between groups.
Refractory breathlessness is a diffi cult clinical problem,
usually the second most common symptom after pain in 40
patients with advanced chronic disease, with high costs
for society.3 Oxygen has a role for individuals with severe
20 hypoxaemia at rest or exercise desaturation, but is of little
symptomatic value when patients are not hypoxic.39 Low-
dose, sustained-release opioids safely reduce breathl ess-
0
ness without respiratory depression,40 but no other
Number at risk Days from consent eff ective drugs exist.1,3,41 Non-pharmacological treatments
Breathlessness 53 50 35 24 13 4 (eg, rollator devices, fan therapy, breathing control, and
support service muscle strengthening) can provide benefi ts16 as can
Control 52 38 28 18 11 4
multidisciplinary rehabilitation programmes, but in
Figure 2: Kaplan-Meier estimates of survival according to study group advanced disease, many patients are unable to attend or
Survival was calculated from the time of randomisation to the time of death, if death occurred during the study benefi t.16,34 In this context, palliative care can have a role
period, or to the time of censoring (Sept 1, 2013). Median days between randomisation to Sept 1, 2013, was
(panel 2), but robust trials are scarce.
745 (range 338–1075) for the breathlessness support service group and 711 (345–1045) for the control group.
Tick marks show censoring of data. Overall generalised Wilcoxon (Breslow) was 3·90, p=0·048. In subgroup Although the fi nding of improved mastery in patients
analysis, this pattern was not recorded for patients with cancer (0·01, p=0·97; n=21); but it became more marked in the breathlessness support service group might not be
for patients with diseases other than cancer (6·04, p=0·01; n=84). The pattern was recorded for patients with surprising, this service (integrated palliative and
chronic obstructive pulmonary disease and separately in those with interstitial lung disease, although numbers are
respiratory care) is not standard, and usual care did not
small for those with interstitial lung disease.
achieve the same result. All patients had advanced and
At 6 weeks, we noted no signifi cant diff erences between deteriorating disease, in the palliative phase of a
total formal care costs in the two groups. 6 week mean progressive illness, in which breathlessness progressively
costs were £1422 in the breathlessness support service increases up to death. Therefore, the fi nding of little
group (bootstrapped 95% CI 897–2101) and £1408 in the change in our secondary outcomes is not surprising,
control group (899–2023). Costs varied greatly between especially ones such as spirometry. These data suggest
individuals. that we included an appropriate group of patients.
984 www.thelancet.com/respiratory Vol 2 December 2014
)%(
lavivrus
tneitaP
Breathlessness
support service
Control
0 200 400 600 800 1000 1200
Articles
The American Thoracic Society defi nes breathlessness
Panel 2: Research in context
as “a subjective experience of breathing discomfort that
consists of qualitatively distinct sensations that vary in Systematic review
intensity”.3 Like pain, breathlessness is a subjective In the past 4 years there have been calls for early integration of palliative care to support
experience resulting from complex interactions between patients with advanced disease.10,11 We searched the scientifi c literature for evidence by
pathological, physiological, and emotional elements. extending three systematic reviews and one narrative review that assessed early palliative
Therefore, it is diffi cult to choose the correct outcome to care in hospitals and at home.26–30 We updated their search terms and also searched for any
measure in breathlessness trials. We chose a well studies with the keywords: palliative, integration, and early. Additionally, we searched for
established quality of life measure’s mastery domain, trials of service interventions for patients with breathlessness (or dyspnoea or dyspnea) in
rather than levels of breathlessness, for several reasons. advanced diseases (chronic obstructive pulmonary disease [COPD] or interstitial lung
First, ratings of breathlessness levels are very variable disease or heart failure or cancer) and on refractory breathlessness. Although many
and patients can have breathlessness attacks several qualitative and descriptive studies have been done, we identifi ed only four trials of early
times a day without constant breathlessness. Therefore, palliative care; three of these for patients with cancer. Temel and colleagues31 and Bakitas
helping these patients to master their attacks might be and colleagues32 found early palliative care signifi cantly improved quality of life; the recent
more important than reducing the severity of one attack. Zimmermann and coworkers trial28 found similar benefi ts. In non-cancer, there is one
Second, breathlessness is a limited endpoint because published phase 2 trial of early palliative care in patients with multiple sclerosis, which
people perform activity to the highest level of suggested early integrated palliative care improved symptom control.33 Although many
breathlessness they can bear, but hope to do more before interventions and services have been proposed to help patients with chronic
they reach that point. Breathlessness support services breathlessness, such as pulmonary rehabilitation,34 and national initiatives such as
aimed to support and provide patients with coping IMPRESS aimed at the development of integrated population-based approaches to
strategies and interventions to help them master their prevent, detect, and care for people aff ected by COPD,35 there are few for patients with the
breathlessness, while accepting that the disease cannot more advanced stages of illness or refractory breathlessness. We identifi ed two
be cured and its natural history changed. Thus, the randomised trials, one in progress. Bredin and colleagues14 tested a nurse-led clinic for
amount of perceived breathlessness mastery is probably patients with lung cancer, not palliative care. A coauthor of this study, Booth, did
a more important component of quality of life than is observational work15 and is currently trialling a community-based palliative care and
amount of breathlessness. As the qualitative results physiotherapy service, the breathlessness intervention service, but this does not have
suggest, patients found this point important. out-patient clinics or include respiratory medicine.36 In Canada, Rocker and Cook37
We found a diff erence in survival between study developed the INSPIRED model of care for patients with advanced COPD to off er a more
groups; patients in the control group had poorer survival integrated approach to care, with personalised action plans, advance care planning, and
in the early period of the study compared with patients palliative treatments. We could fi nd no randomised trials of INSPIRED but observational
in the breathlessness support service group. This data suggest the model reduces repeat admissions and is welcomed by patients. Horton
diff erence was not found for patients with cancer, but and colleagues38 did an observational study to test the feasibility of home-based palliative
was signifi cant for patients with diseases other than care for patients and caregivers living with advanced COPD (30 patients enrolled and
cancer, mostly in those with COPD and interstitial lung 13 provided outcome assessments).
disease. We do not have reliable data for the longevity of
the disease or prognosis before randomisation, which Interpretation
limits interpretation of this fi nding. However, our In this randomised controlled trial of 105 patients with refractory breathlessness, we
results support another trial of early palliative care,31 noted that patients who received an integrated palliative care and respiratory
although we are the fi rst to fi nd a survival diff erence for breathlessness support service had signifi cantly improved breathlessness mastery at
patients with diseases other than cancer. Therefore, 6 weeks. Mastery assessed patients’ feeling of control over their breathlessness and its
these results need further exploration and testing in eff ects on quality of life and function, and was on average 16% higher for those patients
future trials, as does the optimum timing of the receiving the breathlessness support service. The breathlessness support service did not
breathlessness support service. show a signifi cant advantage for other secondary outcomes, although there was a
The breathlessness support service had some similar tendency for improvement in the ability to undertake activities of daily living, lesser
components to the breathlessness intervention service depression, and lower breathlessness on exertion. Our fi ndings were supported by
developed in Cambridge, UK in the late 2000s,15 including qualitative data. We did not fi nd a diff erence in formal care costs. Like Temel and
one point of entry, integration of palliative care with colleagues’ trial,31 survival was better for the group receiving early breathlessness support
physiotherapy, some specifi c interventions, and service than the control group, although in this instance for patients with diseases other
education. However, there are diff erences between the than cancer. In both these studies, survival was a secondary outcome, which suggests
services; we included assessment by respiratory medicine further research is needed. Our study supports the early integration of palliative care with
(a component valued by patients in the qualitative respiratory medicine in non-cancer (eg, COPD, interstitial lung disease, and heart failure),
interviews), asked patients to attend outpatient clinics focused on a group with refractory breathlessness. By being based mainly in outpatient
(the breathlessness intervention service is home based), settings and for a short term, the breathlessness support service meets the Block and
and used the poem for crisis management. Billings criteria of being scalable.11 As our trial was of one service, we suggest that the
Our study has limitations. We were only able to single breathlessness support service warrants testing in multicentre randomised trials, and
mask the groups. Our primary outcome measure was further studies comparing diff erent models and the timing of integration are needed.
subjective; patients who knew their study group could
www.thelancet.com/respiratory Vol 2 December 2014 985
Articles
have been subject to the placebo eff ect. However, Declaration of interests
participants were unaware that mastery was an We declare no competing interests.
endpoint because it was not emphasised in interviews Acknowledgments
and relevant questions were dispersed within the This study was funded mainly by a National Institute for Health Research
(NIHR) grant from Research for Patient Benefi t (PBPG-0808-17311). This
questionnaire. Additionally, the research nurse could
report presents independent research funded by the NIHR under its
have seen breathlessness support service equipment Research for Patient Benefi t (RfPB) programme (PB-PG-0808-17311). The
(eg, hand-held fan and information sheets) in the views expressed are those of the authors and not necessarily those of the
home, which could have biased their interviews. Our NHS, the NIHR, or the Department of Health. Additional support for the
work and interviews was from an NIHR senior investigator award and
inclusion and exclusion criteria prevented extrapolation
the Cicely Saunders International breathlessness programme. The
of study results to patients in the last month of life. UKCRC-registered King’s Clinical Trials Unit at King’s Health Partners is
Further, our outcome follow-up was short because of part funded by the National Institute for Health Research (NIHR)
the fast-track nature of the trial. Although this short Biomedical Research Centre for Mental Health at South London and
Maudsley NHS Foundation Trust and King’s College London and the
follow-up gave us acceptability from referrers and
NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC).
patients, it restricted our assessments, especially of The funders of the study had no role in protocol design, collection or
care costs and long-term survival; the trial was not analysis of the data, or interpretation or writing of the results. We thank
designed specifi cally to test for survival. We recruited all the patients who participated in this research; everybody who
identifi ed and screened patients for this study, especially the Palliative
from a small number of sites in urban areas where
Care, Respiratory Medicine and Physiotherapy Departments at King’s
usual care at specialist centres was probably of an College Hospital (London, UK), and the Community Palliative Care
unusually good standard, with expert staff who were teams across Guy’s and St Thomas’ Hospitals (London, UK); H Bellas
motivated to take part in this research. We were unable (physiotherapist), E Brink (social worker), J Kelly (clinical nurse
specialist), and the occupational therapists for their input in the delivery
to contact more than a fi fth of patients screened and
of breathlessness support service, and C Pannell and S de Wolf-Linder
eligible for the study, and could not pursue this further (research nurses) for their interviews with patients; members of our
because of data protection and ethics approval project advisory group for their advice during the course of the study and
requirements. Therefore, we do not know how our in particular J Taylor of St Christopher’s Hospice (London, UK) for
allowing us to use the Breathlessness poem; C Murphy and colleagues at
recorded eff ects translate to other routine scenarios and
the Clinical Trials Unit at King’s Health Partners for their support in the
settings. Some patients were identifi ed via palliative randomisation, D Yi for support of the economic analysis, and
care services, which might have aff ected our results; M Costantini for comments on an earlier draft of this paper; and J Fuller
and J Davies for providing administrative support during this project.
however, the diff erence in our primary outcome
remained when these eff ects were excluded. References
1 Currow DC, Abernethy AP, Ko DN. The active identifi cation and
Our primary outcome had an eff ect size of 0·44,
management of chronic refractory breathlessness is a human right.
smaller than that proposed in our sample size calculation. Thorax 2014; 69: 393–94.
Puhan and colleagues20 recommended an eff ect size of 2 Gysels MH, Higginson IJ. The lived experience of breathlessness
and its implications for care: a qualitative comparison in cancer,
0·7 for patient self-administered and 0·38 for interviewer-
COPD, heart failure and MND. BMC Palliat Care 2011; 10: 15.
administered questionnaires. We fi nd it surprising that a 3 Parshall MB, Schwartzstein RM, Adams L, et al. An offi cial
diff erence in interviewer should make such a diff erence American Thoracic Society statement: update on the mechanisms,
assessment, and management of dyspnea.
in eff ect size, although this might be related to less
Am J Respir Crit Care Med 2012; 185: 435–52.
variation in interviewer-administered formats. However,
4 Sorenson HM. Palliative care for lung disease: start early, stay late.
perhaps we should have used the more conservative Lancet Respir Med 2013; 1: 279–80.
0·38 in our sample size estimation. 5 Solano JP, Gomes B, Higginson IJ. A comparison of symptom
prevalence in far advanced cancer, AIDS, heart disease, chronic
This trial provides support for a more integrated
obstructive pulmonary disease and renal disease.
approach to management of breathlessness within a J Pain Symptom Manage 2006; 31: 58–69.
breathlessness support service, which improves patient 6 Austin J, Williams R, Ross L, Moseley L, Hutchison S. Randomised
controlled trial of cardiac rehabilitation in elderly patients with
mastery without aff ecting overall care costs. The recorded
heart failure. Eur J Heart Fail 2005; 7: 411–17.
improvement in survival needs further investigation. 7 Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance
The breathlessness support service needs testing in status and symptom scores for patients with cancer during the last
six months of life. J Clin Oncol 2011; 29: 1151–58.
multicentre, longer term trials including a wider range of
8 Barbera L, Taylor C, Dudgeon D. Why do patients with cancer visit
urban and rural settings. the emergency department near the end of life? CMAJ 2010;
182: 563–68.
Contributors
9 Bausewein C, Booth S, Gysels M, Kuhnbach R, Haberland B,
IJH, CB, CJJ, WG, PMC, and JM conceived the idea of the study and
Higginson IJ. Understanding breathlessness: cross-sectional
secured funding. IJH, CB, CJJ, CCR, and JM set up the study. JM, CCR,
comparison of symptom burden and palliative care needs in
CJJ, and IJH provided the intervention. CB and CCR oversaw the study.
chronic obstructive pulmonary disease and cancer. J Palliat Med
CCR checked and cleaned the data. CCR, WG, and IJH analysed the 2010; 13: 1109–18.
quantitative data, MG the qualitative data, and MD and PMC the
10 The Lancet. Prioritising palliative care. Lancet 2014; 383: 1694.
economic data. SB provided critical comment and advice on the protocol,
11 Block SD, Billings JA. A need for scalable outpatient palliative care
set up, intervention modelling, and analysis stages. IJH, CB, and CCR
interventions. Lancet 2014; 383: 1699–700.
produced the fi rst draft of the paper. All authors commented on and
12 Bausewein C, Jolley C, Reilly C, et al. Development, eff ectiveness
contributed to the fi nal draft. IJH is the guarantor. All authors had full
and cost-eff ectiveness of a new out-patient Breathlessness Support
access to all of the data of the study and take responsibility for the Service: study protocol of a phase III fast-track randomised
integrity of the data and the accuracy of the data analysis. controlled trial. BMC Pulm Med 2012; 12: 58.
986 www.thelancet.com/respiratory Vol 2 December 2014
Articles
13 Altman DG. Practical statistics for medical research, 1st edn. 29 Dalgaard KM, Bergenholtz H, Nielsen ME, Timm H. Early
London: Chapman & Hall, 1991. integration of palliative care in hospitals: a systematic review on
14 Bredin M, Corner J, Krishnasamy M, Plant H, Bailey C, A’Hern R. methods, barriers, and outcome. Palliat Support Care 2014;
Multicentre randomised controlled trial of nursing intervention for published online March 13 DOI:10.1017/S1478951513001338.
breathlessness in patients with lung cancer. BMJ 1999; 318: 901–14. 30 Gomes B, Calanzani N, Curiale V, McCrone P, Higginson IJ.
15 Booth S, Moff at C, Farquhar M, Higginson IJ, Burkin J. Developing Eff ectiveness and cost-eff ectiveness of home palliative care services
a breathlessness intervention service for patients with palliative and for adults with advanced illness and their caregivers.
supportive care needs, irrespective of diagnosis. J Palliat Care 2011; Cochrane Database Syst Rev 2013; 6: CD007760.
27: 28–36. 31 Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for
16 Bausewein C, Booth S, Gysels M, Higginson IJ. Non-pharmacological patients with metastatic non-small-cell lung cancer. N Engl J Med
interventions for breathlessness in advanced stages of malignant and 2010; 363: 733–42.
non-malignant diseases. Cochrane Database Syst Rev 2008; 32 Bakitas M, Lyons KD, Hegel MT, et al. Eff ects of a palliative care
11: CD005623. intervention on clinical outcomes in patients with advanced cancer:
17 Malik FA, Gysels M, Higginson IJ. Living with breathlessness: a the Project ENABLE II randomized controlled trial. JAMA 2009;
survey of caregivers of breathless patients with lung cancer or heart 302: 741–49.
failure. Palliat Med 2013; 27: 647–56. 33 Higginson IJ, McCrone P, Hart SR, Burman R, Silber E,
18 Bausewein C, Booth S, Gysels M, Kuhnbach R, Haberland B, Edmonds PM. Is short-term palliative care cost-eff ective in multiple
Higginson IJ. Individual breathlessness trajectories do not match sclerosis? A randomized phase II trial. J Pain Symptom Manage
summary trajectories in advanced cancer and chronic obstructive 2009; 38: 816–26.
pulmonary disease: results from a longitudinal study. Palliat Med 34 D-C Man W, Polkey MI, Donaldson N, Gray BJ, Moxham J.
2010; 24: 777–86. Community pulmonary rehabilitation after hospitalisation for acute
19 Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. exacerbations of chronic obstructive pulmonary disease:
A measure of quality of life for clinical trials in chronic lung randomised controlled study. BMJ 2004; 329: 1209.
disease. Thorax 1987; 42: 773–78. 35 Williams S, Baxter N, Holmes S, Restrick L, Scullian J, Ward M.
20 Puhan MA, Guyatt GH, Goldstein R, et al. Relative responsiveness IMPRESS Guide to the relative value of interventions for people
of the Chronic Respiratory Questionnaire, St. Georges Respiratory with COPD. A population-based approach to improving outcomes
Questionnaire and four other health-related quality of life for people with chronic obstructive pulmonary disease based on the
instruments for patients with chronic lung disease. Respir Med cost of delivering those outcomes. London: British Thoracic Society
2007; 101: 308–16. and the Primary Care Respiratory Society UK, 2012. http://www.
21 Hearn J, Higginson IJ. Development and validation of a core impressresp.com/index.php?option=com_docman&task=doc_
outcome measure for palliative care: the palliative care outcome view&gid=51&Itemid=82 (accesssed Sept 18, 2014).
scale. Palliative Care Core Audit Project Advisory Group. 3 6 Farquhar MC, Prevost AT, McCrone P, et al. Study protocol: phase
Qual Health Care 1999; 8: 219–27. III single-blinded fast-track pragmatic randomised controlled trial
22 US Department of Health and Human Services, Food and Drug of a complex intervention for breathlessness in advanced disease.
Administration. Guidance for industry. Clinical trial endpoints for Trials 2011; 12: 130.
the approval of cancer drugs and biologics. Department of Health 37 Rocker GM, Cook D. ‘INSPIRED’ approaches to better care for
and Human Services. 2007. http://www.fda.gov/downloads/ patients with advanced COPD. Clin Invest Med 2013; 36: 114–20.
Drugs/.../Guidances/ucm071590.pdf (accessed Aug 18, 2014). 38 Horton R, Rocker G, Dale A, Young J, Hernandez P, Sinuff T.
23 Little RJ, D’Agostino R, Cohen ML, et al. The prevention and Implementing a palliative care trial in advanced COPD: a feasibility
treatment of missing data in clinical trials. N Engl J Med 2012; assessment (the COPD IMPACT study). J Palliat Med 2013;
367: 1355–60. 16: 67–73.
24 Crowley J, Breslow N. Statistical analysis of survival data. 39 Abernethy AP, McDonald CF, Frith PA, et al. Eff ect of palliative
Annu Rev Public Health 1984; 5: 385–411. oxygen versus room air in relief of breathlessness in patients with
25 Curtis L. Unit costs of health and social care. Canterbury: PSSRU refractory dyspnoea: a double-blind, randomised controlled trial.
Canterbury, 2012. Lancet 2010; 376: 784–93.
26 Zimmermann C, Riechelmann R, Krzyzanowska M, Rodin G, 40 Currow DC, Ekstrom M, Abernethy AP. Opioids for chronic
Tannock I. Eff ectiveness of specialized palliative care: a systematic refractory breathlessness: right patient, right route? Drugs 2014;
review. JAMA 2008; 299: 1698–709. 74: 1–6.
27 Greer JA, Jackson VA, Meier DE, Temel JS. Early integration of 41 Simon ST, Higginson IJ, Booth S, Harding R, Bausewein C.
palliative care services with standard oncology care for patients with Benzodiazepines for the relief of breathlessness in advanced
advanced cancer. CA Cancer J Clin 2013; 63: 349–63. malignant and non-malignant diseases in adults.
Cochrane Database Syst Rev 2010; 1: CD007354.
28 Zimmermann C, Swami N, Krzyzanowska M, et al. Early palliative
care for patients with advanced cancer: a cluster-randomised
controlled trial. Lancet 2014; 383: 1721–30.
www.thelancet.com/respiratory Vol 2 December 2014 987
